4.8 Article

Changes in Forced Expiratory Volume in 1 Second over Time in COPD

期刊

NEW ENGLAND JOURNAL OF MEDICINE
卷 365, 期 13, 页码 1184-1192

出版社

MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMoa1105482

关键词

-

资金

  1. GlaxoSmithKline
  2. AstraZeneca
  3. Boehringer Ingelheim
  4. Chiesi
  5. Novartis
  6. Nycomed
  7. Pfizer
  8. Forest Laboratories
  9. Almirall
  10. Esteve
  11. Roche
  12. Merck and Novartis
  13. Aeris
  14. Rox Medical
  15. GlaxoSmithKline and Spiration
  16. Able Associates
  17. Adelphi Research
  18. APT Pharma/Britnall
  19. Aradigm
  20. CommonHealth
  21. Consult Complete
  22. COPDforum
  23. Datamonitor
  24. Decision Resources
  25. Defined Health
  26. Dey
  27. Dunn Group
  28. Easton Associates
  29. Equinox
  30. Forest
  31. Gerson
  32. InfoMed
  33. KOL Connection
  34. M. Pankove
  35. MedaCorp
  36. MDRx Financial
  37. Mpex
  38. Oriel Therapeutics
  39. Otsuka
  40. Pennside
  41. Parma Ventures
  42. Pearl
  43. Pharmaxis
  44. Price Waterhouse
  45. Propagate
  46. Pulmatrix
  47. Reckner Associates
  48. Recruiting Resources
  49. Sankyo
  50. Schlesinger Medical
  51. Scimed
  52. Sudler and Hennessey
  53. TargeGen
  54. Theravance
  55. United BioSource
  56. Uptake Medical
  57. VantagePoint Management
  58. Convergent Health Solutions for Reviews and Trends in COPD
  59. COPD Foundation
  60. Creative Educational Concepts
  61. France Foundation
  62. Information TV
  63. Network for Continuing Education (CHARM)
  64. Novartis (Horsham)
  65. Biomarck
  66. Centocor
  67. Nabi
  68. MRC [G0901697, G0901786] Funding Source: UKRI
  69. Medical Research Council [G0901697, G0901786] Funding Source: researchfish

向作者/读者索取更多资源

BACKGROUND A key feature of chronic obstructive pulmonary disease (COPD) is an accelerated rate of decline in forced expiratory volume in 1 second (FEV(1)), but data on the variability and determinants of this change in patients who have established disease are scarce. METHODS We analyzed the changes in FEV1 after administration of a bronchodilator over a 3-year period in 2163 patients. A random-coefficient model was used to evaluate possible predictors of both FEV1 levels and their changes over time. RESULTS The mean (+/- SE) rate of change in FEV1 was a decline of 33 +/- 2 ml per year, with significant variation among the patients studied. The between-patient standard deviation for the rate of decline was 59 ml per year. Over the 3-year study period, 38% of patients had an estimated decline in FEV1 of more than 40 ml per year, 31% had a decline of 21 to 40 ml per year, 23% had a change in FEV1 that ranged from a decrease of 20 ml per year to an increase of 20 ml per year, and 8% had an increase of more than 20 ml per year. The mean rate of decline in FEV1 was 21 +/- 4 ml per year greater in current smokers than in current nonsmokers, 13 +/- 4 ml per year greater in patients with emphysema than in those without emphysema, and 17 +/- 4 ml per year greater in patients with bronchodilator reversibility than in those without reversibility. CONCLUSIONS The rate of change in FEV1 among patients with COPD is highly variable, with increased rates of decline among current smokers, patients with bronchodilator reversibility, and patients with emphysema. (Funded by GlaxoSmithKline; ECLIPSE-ClinicalTrials.gov number, NCT00292552.)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据